Printer Friendly

SOMATIX NAMES EXECUTIVE VICE PRESIDENT OF COMMERCIAL DEVELOPMENT

SOMATIX NAMES EXECUTIVE VICE PRESIDENT OF COMMERCIAL DEVELOPMENT
 ALAMEDA, Calif., July 6 /PRNewswire/ -- Somatix Therapy Corp. (NASDAQ: SOMA) today announced the appointment of Edward Lanphier to the newly created position of executive vice president of commercial development. Lanphier, 36, was most recently senior vice president of business development and marketing at Celtrix Pharmaceuticals Inc., a publicly traded biopharmaceutical company. Previous to that, he was president and chief executive officer of BioGrowth Inc., a privately held development stage company, where he initiated and negotiated the merger of BioGrowth with Celtrix. Lanphier has an extensive background in corporate development, including positions with Biotherapeutics Inc.; Synergen Inc. and Eli Lilly & Co.
 David Carter, president and chief executive officer of Somatix, stated, "Ed Lanphier has an impressive record of accomplishments with a broad range of health care entities, including established pharmaceutical concerns as well a variety of biotechnology companies. In his new position he will address the tactical and strategic issues surrounding the commercialization of gene therapy."
 According to Edward Lanphier, "I am looking forward to working with David and the rest of the Somatix management staff. The company has assembled an excellent cadre of researchers and is now putting together the team that will be responsible for commercializing its research. I am certain it will be an exciting and stimulating task."
 Somatix Therapy Corp. is a scientific leader in the emerging field of gene therapy. The company is focused on the genetic modification of selected human cells to enable the production and delivery of therapeutic substances within the patient's body. Somatix believes that gene therapy, which requires gene transfer technology, will provide a safe and effective means of delivering many therapeutic substances. Somatix has gene therapy programs in cancer, central nervous system diseases and hemophilia.
 -0- 7/6/92
 /CONTACT: Julie Wood of Somatix, 510-748-3082/
 (SOMA) CO: Somatix Therapy Corp. ST: California IN: MTC SU: PER


MC -- SF001 -- 6527 07/06/92 09:30 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 6, 1992
Words:322
Previous Article:TELECONCEPTS RECEIVES FIRM COMMITMENTS FOR EQUITY PLACEMENT IN EXCESS OF MINIMUM REQUIRED FOR MERGER WITH THERMASCAN, INC.
Next Article:GRANCARE APPOINTS NEW BOARD MEMBER
Topics:


Related Articles
SOMATIX RAISES ADDITIONAL $5.2 MILLION: OVERALLOTMENT OPTION EXERCISED
SOMATIX NAMES SOFRONIEW TO HEAD NEURAL PROGRAM
SOMATIX ADDS NEUROSCIENTIST
SOMATIX ANNOUNCES COLLABORATION WITH THE CALIFORNIA PARKINSON'S FOUNDATION
SOMATIX REPORTS THIRD QUARTER RESULTS
BRISTOL-MYERS SQUIBB INVESTS IN SOMATIX; COMPANIES TO EVALUATE POSSIBLE AREAS FOR COLLABORATION IN GENE THERAPY
Cell Genesys and Somatix Agree to Merge
Cell Genesys/Somatix Merger Completed

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters